BDSI - BioDelivery Sciences International, Inc.

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by anotherdevilsadvocate, Jul 7, 2021.

  1. anotherdevilsadvocate

    anotherdevilsadvocate Well-Known Member

    Joined:
    Apr 3, 2016
    Messages:
    4,319
    Likes Received:
    3,375
    [​IMG]
    BioDelivery Sciences International, Inc.
    Healthcare | Biotechnology | USA

    BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.
     
  2. anotherdevilsadvocate

    anotherdevilsadvocate Well-Known Member

    Joined:
    Apr 3, 2016
    Messages:
    4,319
    Likes Received:
    3,375
    Small $370 million pharma company that made a move on volume today.
    Had been trading sideways for a month; it has been going up since last ER. They are already profitable, this is not a clinical stage biotech.
    Currently P/E is 15, and EPS is forecast to triple in 2 years.
    [​IMG]
     

Share This Page